Viridian Therapeutics Past Earnings Performance
Past criteria checks 0/6
Viridian Therapeutics's earnings have been declining at an average annual rate of -36.2%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 36.5% per year.
Key information
-36.2%
Earnings growth rate
28.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -36.5% |
| Return on equity | -53.8% |
| Net Margin | -75,711.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt
Sep 12
Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?
May 15Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?
Apr 18Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?
Jan 08Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market
Sep 09Viridian Therapeutics board compensation committee approves inducement grants
Sep 02An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued
Aug 22Viridian Therapeutics Q2 2022 Earnings Preview
Aug 12Viridian Therapeutics gets a new COO
Jun 23Viridian Therapeutics (VRDN) Investor Presentation - Slideshow
Jun 08Viridian Therapeutics reports Q1 results
May 06Revenue & Expenses BreakdownBeta
How Viridian Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -238 | 95 | 0 |
| 30 Sep 23 | 0 | -217 | 72 | 0 |
| 30 Jun 23 | 1 | -198 | 60 | 0 |
| 31 Mar 23 | 2 | -172 | 49 | 0 |
| 31 Dec 22 | 2 | -130 | 35 | 0 |
| 30 Sep 22 | 2 | -113 | 32 | 0 |
| 30 Jun 22 | 1 | -98 | 30 | 0 |
| 31 Mar 22 | 2 | -87 | 28 | 0 |
| 31 Dec 21 | 3 | -79 | 26 | 0 |
| 30 Sep 21 | 3 | -141 | 24 | 0 |
| 30 Jun 21 | 3 | -133 | 21 | 0 |
| 31 Mar 21 | 2 | -121 | 17 | 0 |
| 31 Dec 20 | 1 | -111 | 13 | 0 |
| 30 Sep 20 | 2 | -30 | 10 | 0 |
| 30 Jun 20 | 3 | -36 | 11 | 0 |
| 31 Mar 20 | 5 | -38 | 11 | 0 |
| 31 Dec 19 | 4 | -42 | 12 | 0 |
| 30 Sep 19 | 4 | -42 | 12 | 0 |
| 30 Jun 19 | 4 | -40 | 12 | 0 |
| 31 Mar 19 | 4 | -40 | 11 | 0 |
| 31 Dec 18 | 8 | -33 | 11 | 0 |
| 30 Sep 18 | 9 | -29 | 11 | 0 |
| 30 Jun 18 | 10 | -26 | 11 | 0 |
| 31 Mar 18 | 8 | -24 | 11 | 0 |
| 31 Dec 17 | 4 | -27 | 11 | 0 |
| 30 Sep 17 | 3 | -26 | 11 | 0 |
| 30 Jun 17 | 3 | -24 | 10 | 0 |
| 31 Mar 17 | 3 | -21 | 9 | 0 |
| 31 Dec 16 | 3 | -17 | 7 | 0 |
| 30 Sep 16 | 4 | -17 | 5 | 0 |
| 31 Dec 15 | 5 | -16 | 4 | 0 |
| 31 Dec 14 | 8 | -6 | 4 | 0 |
Quality Earnings: VRDN is currently unprofitable.
Growing Profit Margin: VRDN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VRDN is unprofitable, and losses have increased over the past 5 years at a rate of 36.2% per year.
Accelerating Growth: Unable to compare VRDN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VRDN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: VRDN has a negative Return on Equity (-53.78%), as it is currently unprofitable.